Qing-Xin-Jie-Yu Granules in addition to conventional treatment for patients with stable coronary artery disease (QUEST Trial): study protocol for a randomized controlled trial

Abstract

BackgroundRecurrent cardiovascular event remains high in stable coronary artery disease (SCAD), especially in patients with multiple risk factors, despite a high rate of use conventional treatment. Traditional Chinese Medicine (TCM) is a promising complementary and alternative medicine for treating SCAD, while evidence for its effect on long-term survival is limited. This study was designed to test if Chinese herbal medicine in addition to conventional treatment is more effective than conventional treatment alone in reducing major adverse cardiac event (MACE) for SCAD patients with multiple risk factors during a 1-year follow-up.MethodsThis is a multicenter, placebo-controlled, double-blinded, randomized controlled clinical trial. A total of 1500 patients are randomized in a 1:1 ratio to receive the Qing-Xin-Jie-Yu Granules (QXJYG) or the placebo granules, twice daily for 6 months. The primary outcome is the combined outcomes including cardiac death, nonfatal myocardial infarction and revascularization. The secondary outcome is the combined outcomes including all-cause mortality, re-admission for acute coronary syndrome (ACS), heart failure, malignant supraventricular and ventricular arrhythmia influencing hemodynamics, ischemic stroke, and other thromboembolic events during 1-year follow-up. The assessment is performed at baseline (before randomization), 1, 3, 6, 9, and 12 months after randomization.DiscussionThis is the first multicenter trial sponsored by the national funding of China to evaluate TCM in combination with conventional treatment on 1-year survival in high-risk SCAD patients. If successful, it will provide an evidence-based complementary therapeutic approach for reducing MACE from SCAD.Trial registrationThe trial was registered in the Chinese Clinical Trial Registry on December 28, 2013. The registration number is ChiCTR-TRC-13004370.Electronic supplementary materialThe online version of this article (doi:10.1186/s13063-016-1569-9) contains supplementary material, which is available to authorized users.

Effect of Wenxin Granules on Gap Junction and MiR-1 in Rats with Myocardial Infarction

“…Recently, traditional Chinese herbal medicine has become more accepted and accessible both in the East and West [9, 10]. Traditional Chinese herbal medicine can provide the first step of early and preventive therapy by reducing the risk of a cardiovascular event [11]. Moreover, many of the traditional Chinese herbal medicines are characterized by good tolerability combined with relatively high efficiency and low price which makes them promising for the long term preventive treatment of members of risk groups.…”

“…In China, traditional Chinese herbal medicine has been used to prevent and treat cardiovascular system diseases, including arrhythmia, for thousands of years. Several studies have shown that a combination of traditional Chinese herbal medicine and conventional western medicine could prevent significantly the occurrence of malignant arrhythmia and reduce the mortality caused by SCD in MI patients [11–13]. …”

Tongmai Yangxin intervening in myocardial remodeling after PCI for coronary heart disease: study protocol for a double-blind, randomized controlled trial

“…Women of childbearing age will be tested for pregnancy by urine examination at enrollment. The National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grading system will be used to classify the nature and severity of AEs [8].…”

The Efficacy and Safety of Chinese Medicine Fufang Zhenzhu Tiaozhi Capsule (FTZ) in the Treatment of Diabetic Coronary Heart Disease: Study Protocol for Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

“…18,19 Currently, the number of clinical trials about the efficacy of Chinese herbal medicine (CHM) in treating CHD increases greatly. [20][21][22][23][24] Different from CHD, however, DCHD is also related to various factors of glucolipid metabolism disorder. In the theory of TCM, the key pathogenesis of DCHD is "Gan-depression and Pi-mistransportion as fundamental, phlegm-dampstasis stagnation as manifestation".…”